TickerTalks
Browse all tickers →
TickerTalks›$NMRA
NMNMRA

Neumora Therapeutics, Inc. Common Stock

$NMRA·$298M·Biotechnology·Healthcare
$1.61-2.4%YTD-8.8%1Y-17.9%
Mentions · last 7 days
2026-07-25: 6 posts2026-07-26: 5 posts2026-07-27: 14 posts2026-07-28: 4 posts2026-07-29: 8 posts2026-07-30: 12 posts2026-07-31: 16 posts65+2%
Price updated 2d ago·X counts updated 2d ago
NMNMRA
$NMRANeumora Therapeutics, Inc. Common Stock
$1.61-2.42%65 posts+2%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $NMRA, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventEvent coming upAI verdict · as of 2026-08-01

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Post-Phase-3-failure biotech at $1.61 printing Aug 5 with securities-fraud investigation open and NLRP3 update pending.

Neumora Therapeutics is a clinical-stage neuro-and-psych biotech; navacaprant (its lead depression asset) failed Phase 3 in June — the stock fell ~50% on the news.

The setup:

  • Revenue $0 (clinical stage); market cap $298M against ongoing quarterly cash burn ~$47M.
  • June 16: Navacaprant failed primary endpoint in KOASTAL-2 and KOASTAL-3 in MDD; discontinued.
  • June 18: Levi & Korsinsky opened a potential securities-fraud investigation.
  • June 15: 8-K disclosed material definitive agreement + $$ obligation + exit costs — restructuring after the trial failure.
  • July 27: Reported favorable NMRA-215 pre-clinical toxicology with planned 2026 clinical advancement — the pipeline pivot beginning.
  • Tape: -9% YTD, -18% t12m, position-in-52w-range 28% — post-crash lows.

Into the print:

  • Q2 print Aug 5; near-term drivers are cash runway, NLRP3 program update (August-flagged), and NMRA-215 clinical timing.

Bottom line: Post-failure clinical biotech re-pivoting to NLRP3 and preclinical assets — high-risk-only into the print.

Agrees with X sentimentX captures the navacaprant failure and management capital-allocation questions; the fact pattern matches (KOASTAL failure, restructuring 8-K, investigation).

What to watch: Aug 5 print — cash runway, NLRP3 development-plan update, NMRA-215 Phase 1 timeline, and any restructuring cost detail.

On the calendar: 2026-08-05 — Q2 2026 earnings

post-phase3-failuresecurities-investigation-openpipeline-pivot

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bearish sentiment7 posts analyzed · as of 2026-06-22

Neumora reported that navacaprant failed to achieve the primary endpoint in both Phase 3 KOASTAL-2 and KOASTAL-3 in major depressive disorder, with the company discontinuing development of the program. The stock fell roughly fifty percent on the news. Holders question management's capital allocation after running two Phase 3 trials on a failed Phase 2b in the most crowded CNS market. The forward narrative shifts to the NLRP3 Inhibitor program with an August update.

Read the AI verdict + X sentiment for $NMRA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage CNS biotech advancing navacaprant, a kappa opioid receptor antagonist, for major depressive disorder and neuropsychiatric conditions.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $NMRA.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $NMRA

Neutral — Clinical-stage CNS biotech advancing navacaprant, a kappa opioid receptor antagonist, for major depressive disorder and neuropsychiatric conditions; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.0%YTD
+40.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-1.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-180%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-66.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-182%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-0.30$-0.32+6.3%
Q4 2025Mar 16, 2026$-0.35$-0.34-2.9%
Q3 2025Nov 6, 2025$-0.35$-0.34-2.9%
Q2 2025Aug 6, 2025$-0.33$-0.38+13.2%
Next earningsWed, Aug 5·consensus EPS $-0.23

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.30$-46.4M
Q4 FY25$0———$-0.35$-47.9M
Q3 FY25$0———$-0.35$-46.6M
Q2 FY25$0———$-0.33$-52.4M

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$625K$625K – $625K-$0.91-$1.26 – -$0.669
FY27$2.9M$2.9M – $2.9M-$0.74-$1.06 – -$0.336
FY28$39.8M$39.8M – $39.8M-$0.73-$1.11 – -$0.188
FY29$123.5M$123.5M – $123.5M-$0.48-$0.48 – -$0.487
FY30$294.2M$294.2M – $294.2M$0.01$0.01 – $0.017

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.28%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-2.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-26.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

β2.775-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellFeb 17Paul L BernsSee Remarks9.8K sh$34KSellFeb 17Milligan Michael LeeSee Remarks1.4K sh$5KSellFeb 17Aurora Daljit SinghSee Remarks6.2K sh$22KSellFeb 17Joshua PintoPresident6.0K sh$21K
+ 5 other (5 awards) in window

See when $NMRA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJun 158-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation · Item 2.05: Restructuring / exit costs · Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Neumora Therapeutics Inc. (NMRA) filed an 8-K on June 15, 2026 covering a material definitive agreement (Item 1.01), creation of a direct financial obligation (Item 2.03), triggering of exit/disposal costs (Item 2.05), a Reg FD disclosure (Item 7.01), and other events (Item 8.01). Body unavailable — excerpt cuts off before the specific agreement terms, obligation amount, or exit-cost details are disclosed.

8-KShareholder voteMay 298-K — Item 5.07: Shareholder vote
AI summary

Neumora Therapeutics Inc. (NMRA) reported annual meeting vote results (Item 5.07) in an 8-K filed May 29, 2026. Body unavailable — excerpt cuts off before specific vote tallies are disclosed.

SC 13D/AActivist amendmentApr 1SC 13D/A
8-KPress release / Reg FDFeb 118-K — Item 7.01: Press release / Reg FD
+ 12 other (4 13Gs · 2 earnings 8-Ks · 2 proxys · 1 routine 8-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026globenewswire.com·7d agoNMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraudgurufocus.com·46d agoNMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraudbusinesswire.com·46d agoNeumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)prnewswire.com·48d agoNeumora Stock Plunges 49% After Late-Stage Depression Drug Failurezacks.com·48d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$REPL$CAPR$IBRX$REGN$AURA$HALO$ALLO$MRNA
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport